🇺🇸 FDA
Patent

US 8183274

Treatment of hyperproliferative disorders with diarylhydantoin compounds

granted A61PA61P13/08A61P17/10

Quick answer

US patent 8183274 (Treatment of hyperproliferative disorders with diarylhydantoin compounds) held by The Regents of the University of California expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61P, A61P13/08, A61P17/10, A61P17/14, A61P35/00